## "A Study Of High-Resolution Ultrasound Of Pheripheral Nerves (Ulnar, Median, Common Peroneal And Tibial) In Diabetic Neuropathy And Its Correlation With Nerve Conduction Study"

#### Dr. M. K Mittal

(M.D Radiodiagnosis, Prof. & Head Of Department Of Radiodiagnosis, Swami Vivekanand Subharti University, Meerut)

#### Dr. Sachin Agrawal

(M.D Radiodiagnosis, Associate Professor Of Department Of Radiodiagnosis, Swami Vivekanand Subharti University, Meerut)

#### Dr. Vishal Vishnoi

(M.D Medicine, Assistant Professor Of Department Of Medicine, Swami Vivekanand Subharti University, Meerut)

### Dr. Umesh Dalal

(Junior Resident, Radiodiagnosis, Swami Vivekanand Subharti University, Meerut)

#### Abstract

**Background:** Diabetic neuropathy is a prevalent complication of both type 1 and type 2 diabetes mellitus (DM). Diabetic peripheral neuropathy (DPN) affects approximately 30% of those with diabetes, primarily impacting the feet and legs, though it can also involve the arms and hands. Neuropathic pain in DPN can affect up to 30% of patients, significantly impairing quality of life, increasing dependence on medication, and correlating with higher morbidity and mortality rates.

Aims and Objective: To assess the cross-sectional area (CSA) of specific peripheral nerves—namely, the median nerve at the wrist, ulnar nerve at the elbow, tibial nerve at the ankle, and common peroneal nerve at the knee in individuals suspected of having DPN. Additionally, it sought to investigate the correlation between CSA measurements and nerve conduction studies (NCS), as well as to explore patterns of nerve involvement and morphological changes in these peripheral nerves.

*Material and Methods:* This cross-sectional observational study was conducted at C.S.S. Hospital, affiliated with S.V.S.U., from February 2023 to August 2024, with approval from the Institutional Ethics Committee. Data were gathered from 70 patients exhibiting symptoms of neuropathy, including both outpatient and inpatient cases. High-resolution ultrasound and Nerve conduction study (NCV) of peripheral nerves was performed on patients diagnosed with Type 2 Diabetes Mellitus (T2DM), based on clinical symptoms and HbA1c levels.

**Conclusion:** Our study demonstrated a positive correlation between increased cross-sectional areas (CSA) of peripheral nerves and abnormalities in nerve conduction studies (NCS). Ultrasound (US) effectively detected morphological changes in nerves before electrodiagnostic issues, indicating its potential for early DPN detection. DPN patients had significantly higher CSA values than those without the condition. We observed distinct NCS patterns: lower limb nerves typically showed axonopathy, while upper limb nerves exhibited more demyelination, underscoring the greater impact on lower limbs in DPN.

Date of Submission: 07-12-2024

Date of Acceptance: 17-12-2024

#### I. Introduction

Diabetic neuropathy is a prevalent complication of both type 1 and type 2 diabetes mellitus (DM), currently affecting around 8.4 million individuals worldwide, with projections indicating this number could rise to over 13 million by 2040.<sup>(1)</sup> DM is characterized by insufficient insulin production or cellular resistance to insulin, resulting in uncontrolled blood sugar levels that can damage nerves and blood vessels.<sup>(2,3)</sup>

Diabetic peripheral neuropathy (DPN) affects approximately 30% of those with diabetes, primarily impacting the feet and legs, though it can also involve the arms and hands. Symptoms include numbness, tingling, and sharp or burning pain, often presenting asymmetrically. Neuropathic pain in DPN can affect up to 30% of patients, significantly impairing quality of life, increasing dependence on medication, and correlating with higher morbidity and mortality rates.<sup>(4-8)</sup>

DPN can manifest in various forms, with symmetric sensory-motor axonal neuropathy being the most common. The exact causes remain unclear but may involve metabolic, neurovascular, autoimmune processes, and lifestyle factors. Diagnosis typically includes clinical assessments, the Toronto Clinical Neuropathy Score (TCNS), and laboratory tests, with high-resolution ultrasonography (HRU) increasingly used for detailed nerve evaluations.<sup>(9-18)</sup>

This study aimed to assess the cross-sectional area (CSA) of specific peripheral nerves—namely, the median nerve at the wrist, ulnar nerve at the elbow, tibial nerve at the ankle, and common peroneal nerve at the knee—in individuals suspected of having DPN. Additionally, it sought to investigate the correlation between CSA measurements and nerve conduction studies (NCS), as well as to explore patterns of nerve involvement and morphological changes in these peripheral nerves.

**Pathophysiology:** Diabetes primarily affects the peripheral nervous system (PNS), making long axons particularly vulnerable to damage. Sensory neurons, especially small unmyelinated C-fibers responsible for transmitting pain and heat sensations, are especially at risk. The progression of DPN leads to degeneration of C-fibers, followed by demyelination of larger fibers and eventual axonal loss, typically resulting in numbness and reduced proprioception that follows a distal-to-proximal pattern.<sup>(19,20)</sup>

**Morphological Changes in Nerve:** High-resolution ultrasonography (HRU) is vital for assessing morphological changes in nerve tissues and diagnosing diabetic peripheral neuropathy (DPN). It evaluates nerve size, vascularity, echogenicity, and mobility, revealing key structural insights. In diabetic patients, a notable change is the enlargement of the nerve cross-sectional area (CSA), often accompanied by a loss of the typical "honeycomb structure." Both longitudinal and transverse nerve diameters increase, and echogenicity decrease and boundary fuzziness are significantly higher than in non-diabetic controls, indicating structural alterations associated with diabetic neuropathy.<sup>(21-26)</sup>

#### II. Materials And Methods:

This cross-sectional observational study was conducted at C.S.S. Hospital, affiliated with S.V.S.U., from February 2023 to August 2024, with approval from the Institutional Ethics Committee. Data were gathered from 70 patients exhibiting symptoms of neuropathy, including both outpatient and inpatient cases. High-resolution ultrasound of peripheral nerves was performed on patients diagnosed with Type 2 Diabetes Mellitus (T2DM), based on clinical symptoms and HbA1c levels, using the Samsung HS50 and HS70 ultrasound machines.

The study excluded individuals with Type 1 or secondary diabetes accompanied by end-organ failure affecting nerve function, those on medications known to induce neuropathy, patients with thyroid disease, a history of severe limb trauma, individuals under 18 years of age, pregnant or lactating women, and those with other forms of neuropathy (such as inflammatory, hereditary, or metabolic).

**Scanning Technique:** Cross-sectional areas (CSAs) of peripheral nerves were measured by tracing their hyperechoic rims, taking three measurements for accuracy. Color Doppler mode was used to exclude blood vessels, and the transducer was applied with minimal pressure. Measurements were taken for the median nerve proximal to the carpal tunnel, the ulnar nerve at the cubital tunnel, the tibial nerve behind the medial malleolus, and the common peroneal nerve at the fibular head in both limbs.<sup>(21)</sup>

#### **Electrodiagnostic Examination (EDX)**

Bilateral nerve conduction studies (NCS) were conducted on the median, ulnar, tibial, and common peroneal nerves in both limbs, using a NEUROWERK diagnostic device in a controlled environment. Participants were asked to remove cosmetics to improve electrical contact.

For tibial nerve assessment, participants lay prone, with electrodes placed near the navicular tubercle and medial malleolus for distal stimulation, and at the popliteal fossa for proximal stimulation. In common peroneal nerve studies, participants lay supine, with electrodes on the extensor digitorum brevis and stimulation near the tibialis anterior tendon and below the fibular head. An accessory deep peroneal nerve was evaluated if the proximal amplitude exceeded the distal.<sup>(27)</sup>

For median nerve sensory studies, electrodes were placed at the wrist and index finger, while for ulnar sensory studies, electrodes were positioned at the wrist and little finger.<sup>(28)</sup> Motor conduction studies assessed

onset latency, peak amplitudes, spike area, and duration, with nerve conduction velocity (NCV) calculated from distance and latency differences. Sensory studies included measurements of onset latency and peak amplitudes.<sup>(29)</sup>

#### **Representative Images:**

(A) Posterior tibial nerve	(B) Common peroneal	(C) Posterior tibial nerve in
in a patient with DPN at	nerve at the neck of <u>fibula</u>	a patient with DPN at
medial malleolus with	with CSA 0.10 cm2 or 10.0	medial malleolus with
CSA 0.07 cm2 or 7.0	mm2 in a patient with	CSA 0.08 cm2 or 8.0 mm2
mm2_	DPN.	and shows decrease in

#### III. Result

Our study found a mean age of 52.06 years (range 23–79) among participants, with illness duration since diagnosis ranging from 2 to 40 years and a mean duration of  $21.04 \pm 8.23$  years. Glycated hemoglobin (HbA1c) levels varied from 5.6 to 14.3%, averaging  $9.03 \pm 2.5\%$ . Table 1 presents the mean cross-sectional area (CSA) of the right upper and lower limb nerves, including the median nerve at the wrist, ulnar nerve at the elbow, tibial nerve at the ankle, and common peroneal nerve at the knee.

### Table 1: Cross Sectional Area (mm2) of Bilateral Limbs Median, Ulnar, Tibial and Common Peroneal Nerves

			14	CI V CS				
Variables	Ν	Minim	Maxim	Mean	Std.	Median	Q1	Q3
		um	um		Deviation			
Median Nerve Right (mm <sup>2</sup> )	70	8.5	13.9	10.484	1.35	10.45	9.30	11.42
Ulnar Nerve Right (mm <sup>2</sup> )	70	7.8	13.6	9.891	1.70	9.20	8.67	10.90
Tibial Nerve Right (mm <sup>2</sup> )	70	5.9	9.8	7.556	0.97	7.50	6.87	8.20
CPN Right (mm <sup>2</sup> )	70	7.8	15.9	11.107	2.13	10.85	9.37	12.72
Median nerve Left (mm <sup>2</sup> )	70	8.4	14.1	10.497	1.56	9.90	9.00	11.62
Ulnar nerve Left (mm <sup>2</sup> )	70	7.8	13.8	9.944	1.62	9.80	8.57	11.15
Tibial nerve Left (mm <sup>2</sup> )	70	5.6	10.0	7.567	1.00	7.40	6.70	8.22
CPN Left (mm <sup>2</sup> )	70	6.7	15.6	10.756	2.10	10.70	8.97	11.90

## Table 2: Nerve wise correlation between diabetic neuropathy and USG measured cross-sectional area (mm<sup>2</sup>) right side of the cases

Variables	Group	N	Mean Of CSA (mm <sup>2</sup> )	Std. Deviation	T value	P value
Median Nerve Right	Diabetic without neuropathy	36	10.17	1.30	-2.029	0.046*
( <b>mm</b> <sup>2</sup> )	Diabetic neuropathy	34	10.82	1.35		
Ulnar Nerve Right	Diabetic without neuropathy	36	9.42	1.49	-2.481	0.016*
( <b>mm</b> <sup>2</sup> )	Diabetic neuropathy	34	10.39	1.78		
Tibial nerve Right	Diabetic without neuropathy	36	7.09	0.83	-4.694	0.000*
( <b>mm</b> <sup>2</sup> )	Diabetic neuropathy	34	8.04	0.87		
CPN Right (mm <sup>2</sup> )	Diabetic without neuropathy	36	10.09	1.79	-4.672	0.000*
	Diabetic neuropathy	34	12.18	1.94		

\*Significant at 5% level of significance

# Table 3: Nerve wise correlation between diabetic neuropathy and USG measured cross-sectional area (mm<sup>2</sup>) left side of the cases

Variables	Group	N	Mean Of CSA (mm <sup>2</sup> )	Std. Deviation	T value	P value
Median nerve Left (mm <sup>2</sup> )	Diabetic without neuropathy	36	10.18	1.43	-1.787	0.078

	Diabetic neuropathy	34	10.84	1.65		
Ulnar nerve Left (mm <sup>2</sup> )	Diabetic without neuropathy	36	9.38	1.39	-3.232	0.002*
	Diabetic neuropathy	34	10.55	1.64		
Tibial nerve Left (mm <sup>2</sup> )	Diabetic without neuropathy	36	7.14	0.84	-4.071	0.000*
	Diabetic neuropathy	34	8.02	0.97		
CPN Left (mm <sup>2</sup> )	Diabetic without neuropathy	36	9.75	1.72	-4.703	0.000*
	Diabetic neuropathy	34	11.82	1.96		

*Significant at 5%	level	of sig	nificance
--------------------	-------	--------	-----------

## Table 4: Nerve wise correlation between NCS pattern and USG measured cross-sectional area right side of the cases

Right side		Norma	d NCS			Axonal				Demyelinating					recordab	F Value	P value	
Cross- sectional area Nerve	Mean	SD	Min	Max	Mean	SD	Min	Max	Mean	SD	Min	Max	Mean	SD	Min	Мах		
Median Nerve	10.5	1.4	8.5	13.9	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ulnar Nerve	9.8	1.7	7.8	13.6	-		-	-	12.8		12.8	12.8	-	-	-	-	1.616	0.206
Tibial Nerve	7.4	.9	5.9	9.8	7.3	.6	6.7	8.2	-	-	-	-	8.5	.6	7.6	9.4	9.166	0.000*
CPN	10.2	1.8	7.8	14.7	11.9	2.0	8.6	15.9	-	-	-	-	13.2	1.5	10.3	15.0	16.826	0.0 00*

\*Significant at 5% level of significance

## Table 5: Nerve wise correlation between NCS pattern and USG measured cross-sectional area left side of the cases

								•	ie cube									
Left side		Norm:	al NCS		Axonal				Demyelinating				Not recordable				F	Р
Cross-								_								Value	value	
sectional	Mean	SD	Min	Max	Mean	SD	Min	Max	Mean	SD	Min	Max	Mean	SD	Min	Max		
area																		
Nerve																		
Median	10.5	1.6	8.4	14.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Nerve	10.5	1.0	0.4	14.1														
Ulnar	9,9	1.6	7.8	13.8	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Nerve	3.5	1.0	1.0	15.6														
Tibial	7.3	1.0	5.6	9.9	7.8	1.0	6.9	10.0	-	-	-	-	8.4	.8	6.8	9.6	6.044	0.004*
Nerve	·	1.0	5.0	7.9	7.0	1.0	0.9	10.0					0.4	ە.	0.8	7.0		
CPN	9.9	1.8	6.7	14.7	10.9	1.6	8.3	13.3	15.6	-	15.6	15.6	13.0	1.4	11.3	15.5	13.873	*000.0

\*Significant at 5% level of significance

In our study, all diabetic patients had normal nerve conduction study (NCS) results for the median nerve, with a mean cross-sectional area (CSA) of  $10.5 \pm 1.4 \text{ mm}^2$  at the wrist for those without diabetic peripheral neuropathy (DPN). For the ulnar nerve, 98.5% had normal NCS results, while 1.42% showed a demyelinating pattern; the CSA at the elbow was  $9.8 \pm 1.7 \text{ mm}^2$  on the right and  $9.9 \pm 1.6 \text{ mm}^2$  on the left for patients without DPN, and 12.8 mm<sup>2</sup> on the right for those with DPN, with no neuropathy detected on the left.

For the tibial nerve, 75.7% had normal NCS results, 10% exhibited an axonal pattern, and 15.7% had non-recordable results. The CSA at the ankle was  $7.09 \pm 0.83$  mm<sup>2</sup> on the right and  $7.14 \pm 0.84$  mm<sup>2</sup> on the left for patients without DPN, compared to  $8.04 \pm 0.87$  mm<sup>2</sup> bilaterally for those with DPN.

In the common peroneal nerve, 60% had normal NCS results, 18.5% showed an axonal pattern, 1.42% had a demyelinating pattern, and 20% had non-recordable results. The CSA at the knee for patients without DPN was  $10.09 \pm 1.79 \text{ mm}^2$  on the right and  $9.75 \pm 1.72 \text{ mm}^2$  on the left, while for those with DPN, it was  $12.18 \pm 1.94 \text{ mm}^2$  on the right and  $11.82 \pm 1.96 \text{ mm}^2$  on the left.

#### IV. Discussion

Our study included 70 diabetic patients suspected of having diabetic peripheral neuropathy (DPN) found a significant correlation between HbA1c levels and nerve cross-sectional area (CSA) (p < 0.05), consistent with Tanu Ranjan et al. and Watanabe et al., but differing from Riazi et al. and Kelle et al.<sup>(3,16,30,31)</sup>

In our ultrasonography assessments of diabetic neuropathy patients, we observed significant nerve changes, including increased cross-sectional area (CSA), loss of the honeycomb pattern, blurred margins, and heightened echogenicity. These alterations are characteristic of diabetic peripheral neuropathy (DPN) and are associated with oxidative stress from microangiopathy and sorbitol buildup in Schwann cells, resulting in axonal damage and demyelination. Similar findings have been reported by Shamrendra Narayan et al., Singh et al., and Ishibashi et al.<sup>(21,26,32)</sup>

In our study, we measured the mean cross-sectional area (CSA) values for nerves as follows: 10.48  $\pm$  1.35 mm<sup>2</sup> for the median nerve, 9.89  $\pm$  1.70 mm<sup>2</sup> for the ulnar nerve, 7.55  $\pm$  0.97 mm<sup>2</sup> for the tibial nerve, and

 $11.10 \pm 2.13 \text{ mm}^2$  for the common peroneal nerve, with identical values on both sides. While our findings align with other studies for upper limb nerves, we observed lower CSA values for the tibial and common peroneal nerves, possibly due to demographic differences. Notably, Tsuneo Watanabe et al. reported higher CSAs for the median and tibial nerves in diabetic patients, while Shamrendra Narayan et al. and Seok Kang et al. found larger CSAs across various nerves.<sup>(16,21,33)</sup>

Nerve conduction studies (NCS) categorized patients into axonal, demyelinating, mixed, and non-recordable groups, with those having normal NCS patterns showing significantly lower CSA values.

We found that lower limb nerves primarily exhibited axonopathy, while upper limb nerves showed more demyelination, aligning with findings by Narayan S. et al.<sup>(21)</sup> In DPN cases, 10% of tibial and 18.5% of common peroneal nerves exhibited axonopathy, with only 1.42% of lower limb nerves showing primary demyelination.

The increased CSA in demyelinating neuropathies indicates thicker nerves, emphasizing NCS's role in differentiating neuropathy types. In advanced cases where NCS may be non-recordable, CSA measurements were higher, reinforcing that diabetic neuropathy initially affects lower limbs before upper limbs, as noted by Narayan S. et al. and Callaghan et al.<sup>(21,34)</sup>

#### V. Conclusion

Our study demonstrated a positive correlation between increased cross-sectional areas (CSA) of peripheral nerves and abnormalities in nerve conduction studies (NCS). Ultrasound (US) effectively detected morphological changes in nerves before electrodiagnostic issues, indicating its potential for early DPN detection. DPN patients had significantly higher CSA values than those without the condition. We observed distinct NCS patterns: lower limb nerves typically showed axonopathy, while upper limb nerves exhibited more demyelination, underscoring the greater impact on lower limbs in DPN.

#### Bibliography

- [1] Ogrotis I, Koufakis T, Kotsa K: Changes In The Global Epidemiology Of Type 1 Diabetes In An Evolving Landscape Of Environmental Factors: Causes, Challenges, And Opportunities. 2023 Mar 28;59(4):668.
- Singh K, Gupta K, Kaur S: High Resolution Ultrasonography Of The Tibial Nerve In Diabetic Peripheral Neuropathy. J Ultrason 2017; 17: 246–252.
- [3] Tanu Ranjan, Shruti Chandak: Role Of High-Resolution Ultrasonography In The Evaluation Of The Tibial And Median Nerves In Diabetic Peripheral Neuropathy. J Ultrason 2022; 22: E209–E215.
- [4] Hicks Cw, Selvin E: Epidemiology Of Peripheral Neuropathy And Lower Extremity Disease In Diabetes. Curr Diab Rep 2019; 19: 1–8.
- Pop-Busui R, Boulton Ajm, Feldman El., Et Al. Diabetic Neuropathy: A Position Statement By The American Diabetes Association. Diabetes Care 2017;40:136–154
- [6] Vileikyte L, Leventhal H, Gonzalez Js, Et Al. Diabetic Peripheral Neuropathy And Depressive Symptoms: The Association Revisited. Diabetes Care 2005;28:2378–2383
- [7] Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian Ja. The Health Care Costs Of Diabetic Peripheral Neuropathy In The Us. Diabetes Care 2003;26:1790–1795
- [8] Kiyani M, Yang Z, Charalambous Lt, Et Al. Painful Diabetic Peripheral Neuropathy: Health Care Costs And Complications From 2010 To 2015. Neurol Clin Pra Ct 2020;10:47–57
- [9] Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., Malik R.A., Maser R.E., Sosenko J.M., Ziegler D., Et Al. Diabetic Neuropathies: A Statement By The American Diabetes Association. Diabetes Care. 2005;28:956–962.
- [10] Diabetic Neuropathy: A Position Statement By The American Diabetes Association. Diabetes Care. 2017;40:136–154.
- [11] Cameron Ne, Eaton Se, Cotter Ma, Tesfaye S. Vascular Factors And Metabolic Interactions In The Pathogenesis Of Diabetic Neuropathy. Diabetologia. 2001;44(11):1973-88.
- [12] Obrosova Ig, Li F, Abatan Oi, Forsell Ma, Komjáti K, Pacher P, Szabó C, Stevens Mj. Role Of Poly(Adp-Ribose) Polymerase Activation In Diabetic Neuropathy. Diabetes. 2004;53(3):711-20.
- [13] Dyck Pj, Overland Cj, Low Pa, Litchy Wj, Davies JI, Dyck Pj Et Al.: Signs And Symptoms Versus Nerve Conduction Studies To Diagnose Diabetic Sensorimotor Polyneuropathy: Cl Vs. Nphys Trial. Muscle Nerve 2010; 42: 157–164.
- [14] Mulder Dw, Lambert Eh, Bastron Ja, Sprague Rg: The Neuropathies Associated With Diabetes Mellitus: A Clinical And Electromyographic Study Of 103 Unselected Diabetic Patients. Neurology 1961; 11: 275–284.
- [15] Dyck Pj, Kratz Km, Karnes Jl, Litchy Wj, Klein R, Pach Jm Et Al.: The Prevalence By Staged Severity Of Various Types Of Diabetic Neuropathy, Retinopathy, And Nephropathy In A Population-Based Cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817–824.
- [16] Watanabe T, Ito H, Sekine A, Katano Y, Nishimura T, Kato Y Et Al.: Sonographic Evaluation Of The Peripheral Nerve In Diabetic Patients: The Relationship Between Nerve Conduction Studies, Echo Intensity, And Cross-Sectional Area. J Ultrasound Med 2010; 29: 697–708.
- [17] Huang H, Wu S: Application Of High-Resolution Ultrasound On Diagnos\_X0002\_Ing Diabetic Peripheral Neuropathy. Diabetes Metab Syndr Obes 2021; 14: 139–152.
- [18] Ismail-Beigi F, Craven T, Banerji Ma, Basile J, Calles J, Cohen Rm Et Al.: Effect Of Intensive Treatment Of Hyperglycaemia On Microvascular Outcomes In Type 2 Diabetes: An Analysis Of The Accord Randomised Trial. Lancet 2010; 376: 419–430.
- [19] Feldman El, Nave K-A, Jensen Ts, Bennett Dlh. New Horizons In Diabetic Neuropathy: Mechanisms, Bioenergetics, And Pain. Neuron 2017;93:1296–1313
- [20] Feldman El, Callaghan Bc, Pop-Busui R, Et Al. Diabetic Neuropathy. Nat Rev Dis Primers 2019;5:41
- [21] Shamrendra Narayan, Amit Goel, Et Al. High Resolution Ultrasonography Of Peripheral Nerves In Diabetic Patients To Evaluate Nerve Cross Sectional Area With Clinical Profile. Br J Radiol 2021; 94: 20200173.
- [22] Ziegler D., Papanas N., Schnell O., Nguyen B.D.T., Nguyen K.T., Kulkantrakorn K., Deerochanawong C. Current Concepts In The Management Of Diabetic Polyneuropathy. J. Diabetes Investig. 2021;12:464–475.

- [23] Afsal M, Chowdhury V, Prakash A, Singh S, Chowdhury N.: Evaluation Of Peripheral Nerve Lesions With High-Resolution Ultrasonography And Color Doppler. Neurol India 2016; 64: 1002–1009.
- [24] Wu X, Ouyang Q, Luo F, Wu S. Evaluation Of Asymmetric Neuropathic Pain With Deec Ultrasound Scoring. Chin J Med Imaging. 2019;27(4):292–297.
- [25] Herraets Ijt, Goedee Hs, Telleman Ja, Et Al. Nerve Ultrasound Improves Detection Of Treatment-Responsive Chronic Inflammatory Neuropathies. Neurology. 2020;94(14):1–10.
- [26] Singh Y, Dixit R, Singh S, Garg S, Chowdhury N. High Resolution Ultrasonography Of Peripheral Nerves In Diabetic Peripheral Neuropathy. Neurol India. 2019;67:S71–S76.
- [27] Jae Yoon Kim, Et Al. Reference Standards For Nerve Conduction Studies Of Individual Nerves Of Lower Extremity With Expanded Uncertainty In Healthy Korean Adults. Ann Rehabil Med 2022;46(1):9-23.
- [28] P. Sepat, S. Wasnik. Sensory Nerve Conduction Study Of Median Ulnar And Radial Nerves In Type 2 Diabetic Individuals In The Age Group 40–80 Years. Heliyon 6 (2020) E05318
- [29] Y.R., Huang C.C., Chiu W.C., Liu R.T., Tsai N.W., Wang H.C., Lin W.C., Cheng B.C., Su Y.J., Su C.M., Et Al. Sural Nerve Sensory Response In Diabetic Distal Symmetrical Polyneuropathy. Muscle Nerve. 2020;61:88–94.
- [30] Riazi S, Bril V, Perkins Ba, Abbas S, Chan Vws, Ngo M, Et Al. Can Ultrasound Of The Tibial Nerve Detect Diabetic Peripheral Neuropathy? A Cross-Sectional Study. Diabetes Care 2012; 35: 2575–9.
- [31] B. Kelle Et Al. Correlation Between Nerve Cross-Sectional Area On Ultrasound And Clinical Features. T Journal Of Back And Musculoskeletal Rehabilitation 29 (2016) 717–722 717.
- [32] Ishibashi Et Al. Morphological Changes Of The Peripheral Nerves Evaluated By High-Resolution Ultrasonography Are Associated With The Severity Of Diabetic Neuropathy, But Not Corneal Nerve Fiber Pathology In Patients With Type 2 Diabete. J Diabetes Invest Vol. 6 No. 3 May 2015
- [33] Kang, S, Et Al. Sonographic Features Of Peripheral Nerves At Multiple Sites In Patients With Diabetic Polyneuropathy. Journal Of Diabetes And Its Complications (2015), 2015.12.008.
- [34] Callaghan Et Al., Diabetic Neuropathy: Clinical Manifestations And Current Treatments. Lancet Neurol. 2012 June; 11(6): 521–534. Doi:10.1016/S1474-4422(12)70065-0.